A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration
A phase 1/2 trial of JAB-23E73 in advanced solid tumours, run by Jacobio Pharmaceuticals Co., Ltd., now recruiting.
Overview
A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration is a phase 1/2 interventional study registered as NCT06959615 by Jacobio Pharmaceuticals Co., Ltd., with 334 participants planned, started 2024-11-22 and due to reach its primary completion in 2026-12-31. Interventions recorded: JAB-23E73.
Similar pages
not linked directly; found by shared links- TrialJAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation
Shares Jacobio Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialJAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
Shares Jacobio Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialJAB-2485 Activity in Adult Patients With Advanced Solid Tumors
Shares Jacobio Pharmaceuticals and the tag pipeline.
- TrialStudy of JAB-23E73 in Combination With Chemotherapy in Participants With Metastatic PDAC Harboring KRAS Gene Alterations
Shares Jacobio Pharmaceuticals and the tag pipeline.
- TrialA First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors
Shares Jacobio Pharmaceuticals and the tag pipeline.
- TrialInvestigation of a Therapeutic Vaccine (ACIT-1) in Cancer
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPlasmodium Immunotherapy for Advanced Malignant Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialFirst-in-Human Study of ICT01 in Patients With Advanced Cancer
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.